List view / Grid view
Next-generation sequencing (NGS) has become the method of choice for many researchers responding to infectious disease outbreaks and in the present coronavirus pandemic. Here, Pushpanathan Muthuirulan discusses the potential of NGS for rapid diagnosis and explores some of the emerging high-throughput approaches using NGS as a readout for the detection…
Genomics England has launched a next-generation genomic research platform that will play a key role in the response to COVID-19. It is hoped this research environment will transform how genomic data is made usable for global biopharma and academic scientists, providing world‑class patient data security, while enabling the flexibility required…
Responding efficiently to urgent situations is of utmost importance in times of crisis. Dr Suvarna Gandlur, Associate Director of Takara Bio’s next-generation sequencing (NGS) portfolio, discusses how the company is contributing to the COVID-19 effort and supporting the scientific community.
In this NGS In-Depth Focus: how next-generation sequencing (NGS) enables rapid detection of viruses and a novel NGS platform advancing genomics research.
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.
The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine, Lauri Paasonen and colleagues explore the potential of using patient-derived cells (PDCs) for devising a personalised treatment strategy for solid tumours.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
Researchers are always looking more effective and efficient ways of making their work more successful. In this supplement, some of our commercial partners share their data, detailing the application of their technology.
Circulating cell-free DNA (cfDNA) has been shown to have potential as a noninvasive substrate for the detection and monitoring of tumour cells. As circulating tumour DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection.
A team of researchers have demonstrated a new way to sequence proteins that are much more sensitive than existing technology, identifying individual protein molecules rather than requiring millions of molecules at a time
Takara Bio has played a major role in the development of single-cell genomics with the launch of kits such as the automation-ready Smart-seq HT, with a simplified 4-steps protocol. In addition, to meetthe demand for using RNA-seq for degraded clinical samples, we have expanded our offering with a complete sequencing…
In this In-Depth Focus: hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of human genetic diseases, and enabling biomarker discovery at single-cell resolution
6 September 2018 | By Takara Bio
The data presented in this application note demonstrates how SMARTer ICELL8 Single-Cell System can be used to generate high-quality RNA-seq libraries that provide full-length transcript sequence information from hundreds of single cells in parallel...
In this issue: pharmacological targeting of mitochondrial dysfunction in Parkinson’s disease, the evolving role of three dimensional in-vitro cell culture techniques in drug discovery, and NGS: hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of genetic diseases.
